Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605463328 | ||
| 003 | CHVBK | ||
| 005 | 20210128100252.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150701xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00774-014-0609-3 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00774-014-0609-3 | ||
| 245 | 0 | 0 | |a Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis |h [Elektronische Daten] |c [Shi Feng, Zhicheng Luo, Da Liu] |
| 520 | 3 | |a The aim of this study was to evaluate the efficacy and safety of odanacatib (ODN) for the treatment of osteoporosis, using data in studies reported in the literature. We performed a literature search to compare the outcomes of applications of once-weekly ODN 50mg and control. The outcomes of osteoporosis evaluated include primary outcome as bone mineral density (BMD) at different skeletal sites, and secondary outcomes, including adverse events (AEs), such as incidence of skin AEs, fracture, and serious adverse events (SAEs). Four trials were included. Mean difference (95% CI) of lumbar spine BMD was 3.41 (1.57-5.24) at 12months and 4.89 (2.72-7.05) at 24months; mean difference (95% CI) of femoral neck BMD was 1.90 (0.73-3.08) at 12months and 3.85 (2.55-5.15) at 24months; mean difference (95% CI) of total hip BMD was 2.65 (1.20-4.09) at 12months and 3.70 (1.76-5.64) at 24months; risk ratio (95% CI) of AEs was 0.98 (0.91-1.07); risk ratio (95% CI) of SAEs was 1.11 (0.72-1.72); risk ratio (95% CI) of skin AEs was 0.92 (0.63-1.35); and risk ratio (95% CI) of fracture was 0.34 (0.16-0.70). In this study, application of 50mg ODN produced significantly greater BMD increases and lower fracture incidence than that of the control. In addition, ODN was generally well tolerated. | |
| 540 | |a The Japanese Society for Bone and Mineral Research and Springer Japan, 2014 | ||
| 690 | 7 | |a Odanacatib |2 nationallicence | |
| 690 | 7 | |a Bone mineral density |2 nationallicence | |
| 690 | 7 | |a Safety |2 nationallicence | |
| 690 | 7 | |a Osteoporosis |2 nationallicence | |
| 690 | 7 | |a Meta-analysis |2 nationallicence | |
| 700 | 1 | |a Feng |D Shi |u Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, 110004, Shenyang, China |4 aut | |
| 700 | 1 | |a Luo |D Zhicheng |u Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, 110004, Shenyang, China |4 aut | |
| 700 | 1 | |a Liu |D Da |u Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, 110004, Shenyang, China |4 aut | |
| 773 | 0 | |t Journal of Bone and Mineral Metabolism |d Springer Japan |g 33/4(2015-07-01), 448-454 |x 0914-8779 |q 33:4<448 |1 2015 |2 33 |o 774 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00774-014-0609-3 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00774-014-0609-3 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Feng |D Shi |u Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, 110004, Shenyang, China |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Luo |D Zhicheng |u Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, 110004, Shenyang, China |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Liu |D Da |u Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Road, 110004, Shenyang, China |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Bone and Mineral Metabolism |d Springer Japan |g 33/4(2015-07-01), 448-454 |x 0914-8779 |q 33:4<448 |1 2015 |2 33 |o 774 | ||